John Francis Lyons

This inventor holds 10 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 5 EPO patents. Top assignees: Astex Therapeutics Limited, Cancer Research Technology Limited, The Institute of Cancer Research: Royal Cancer Hospital. Active years: 2012-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John Francis Lyons. Retrieved from https://idiyas.com/inventor/john-francis-lyons

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 (Patent Applications = 2)

% Patents Active = 10.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 2)

Average Co-Inventor Count = 4.6

ph-index = 4

Forward Citations = 97(Granted Patents)

Location History:

Cambridge, GB (2012 - 2016)
London, GB (2013 - 2022)

Company Filing History:

10 out of 126

Astex Therapeutics Limited

patents

2 out of 268

Cancer Research Technology Limited

patents

1 out of 54

The Institute of Cancer Research: Royal Cancer Hospital

patents

where one patent can have more than one assignee

Years Active: 2012-2022

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11236047 - Combination of isoindolinone derivatives with SGI-110 (2022-02-01),

2. 9428439 - Hydrobenzamide derivatives as inhibitors of Hsp90 (2016-08-30),

3. 8916552 - Pharmaceutical combinations (2014-12-23),

4. 8883790 - Pharmaceutical combinations (2014-11-11),

5. 8779132 - Pharmaceutical compounds (2014-07-15),

6. 8541461 - Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators (2013-09-24),

7. 8435970 - Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea (2013-05-07),

8. 8404718 - Combinations of pyrazole kinase inhibitors (2013-03-26),

9. 8399442 - Pharmaceutical compounds (2013-03-19),

10. 8277807 - Pharmaceutical combinations (2012-10-02),

Title: The Innovative Journey of John Francis Lyons

Introduction: John Francis Lyons is a notable inventor based in Cambridge, GB, who has made significant contributions to the field of medical chemistry. With a portfolio of 10 patents, Lyons has focused his research on developing innovative pharmaceutical solutions.

Latest Patents: Among his latest inventions, Lyons has developed a combination of isoindolinone derivatives with SGI-110, which provides a promising pharmaceutical composition for medical applications. Additionally, he has patented hydrobenzamide derivatives as inhibitors of Hsp90, offering new medical uses and processes for preparing these compounds. His inventions are paving the way for advancements in therapeutic interventions.

Career Highlights: Throughout his career, John Francis Lyons has been associated with reputable companies, including Astex Therapeutics Limited and Cancer Research Technology Limited. His expertise has contributed to research and development efforts, making strides in the pharmaceutical industry.

Collaborations: Lyons has worked alongside distinguished colleagues, including Neil Thomas Thompson and Neil Gallagher. These collaborations highlight the team-oriented approach often seen in innovative research and development settings.

Conclusion: John Francis Lyons continues to be a driving force in the landscape of medical innovations. His dedicated work and numerous patents reflect his commitment to enhancing healthcare through scientific advancements.

Profile summary based on public USPTO records.